Astec LifeSciences Limited Q4 FY25 results press release summary

Results press release of 23 Apr 2025, summarised by AI from the filing.

Management expects uptick in demand for Enterprise & CDMO businesses and gradual improvement in performance in the coming year.

Key takeaways

1. Guidance Management expects uptick in demand for Enterprise & CDMO businesses and gradual improvement in performance in the coming year.
2. Change Q4 FY25 total income rose 25.6% sequentially over Q3 FY25.
3. Driver Q4 improvement driven by higher volumes and prices in Enterprise business and improved product mix in CDMO.
4. Risk Sharp decline in Enterprise product prices and lower CDMO offtakes impacted profitability.

Original filing on BSE

Astec LifeSciences Limited Q1 FY27 results

As filed: Revenue ₹83.6 cr (−8% year on year), EBITDA −₹0.7 cr, PAT −₹18.7 cr, EBITDA margin -0.8% (+1,000 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹159 cr (+32% year on year), EBITDA ₹9.2 cr (+83% year on year), PAT −₹7.8 cr, EBITDA margin 5.8% (+161 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend. EBITDA margin rose 161 bps year on year. Share price after the results: +1.5% in 30 days (Nifty 500: +0.6%).
• Q3 FY26: Revenue ₹125 cr (+33% year on year), EBITDA ₹4.0 cr, PAT −₹15.7 cr, EBITDA margin 3.2% (+957 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend. EBITDA margin rose 957 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +8.5% in 28 days (Nifty 500: +0.4%).
• Q2 FY26: Revenue ₹74.0 cr (−25% year on year), EBITDA −₹7.0 cr, PAT −₹24.0 cr, EBITDA margin -9.5% (+1,000 bps). Score 45 of 100, In line with trend. Revenue growth was below the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue fell 19% from last quarter. Share price after the results: +24.8% in 30 days (Nifty 500: −0.1%).
• Q1 FY26: Revenue ₹91.0 cr (+32% year on year), EBITDA −₹12.0 cr, PAT −₹33.0 cr, EBITDA margin -13.2% (+1,000 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue fell 24% from last quarter. Share price after the results: −6.7% in 29 days (Nifty 500: −1.1%).
• Q4 FY25: Revenue ₹120 cr (−22% year on year), EBITDA ₹5.0 cr (−62% year on year), PAT −₹16.0 cr, EBITDA margin 4.2% (−427 bps). Score 15 of 100, Below trend. Revenue growth was below the company's own trend. EBITDA margin fell 427 bps year on year. Share price after the results: −7.6% in 30 days (Nifty 500: +2.4%).
• Q3 FY25: Revenue ₹94.0 cr (+84% year on year), EBITDA −₹6.0 cr, PAT −₹40.0 cr, EBITDA margin -6.4% (+1,000 bps). Score 15 of 100, Below trend. Revenue growth was well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue fell 5% from last quarter.
• Q2 FY25: Revenue ₹99.0 cr (−11% year on year), EBITDA −₹21.0 cr, PAT −₹39.0 cr, EBITDA margin -21.2% (−1,000 bps). Score 8 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Astec LifeSciences Limited earnings call, investor presentation and press release summaries

• Q3 FY26: Results press release (30 Jan 2026)
• Q2 FY26: Results press release (29 Oct 2025)
• Q1 FY26: Results press release (28 Jul 2025)
• Q4 FY25: Results press release (23 Apr 2025)